| Autor: |
Ramos TI; 1 Departamento de Ciencias de la Vida y la Agricultura, Universidad de las Fuerzas Armadas-ESPE, Quito, Ecuador., Castro KA; 2 Coordinación Nacional de Desarrollo Estratégico en Salud, Ministerio de Salud Pública, Quito, Ecuador., Escalante LS; 2 Coordinación Nacional de Desarrollo Estratégico en Salud, Ministerio de Salud Pública, Quito, Ecuador., Santiago Vispo N; 3 School of Life Sciences & Biotechnology, Yachay Tech University, Urcuquí, Ecuador. |
| Jazyk: |
angličtina |
| Zdroj: |
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2017 May; Vol. 51 (3), pp. 307-313. Date of Electronic Publication: 2016 Dec 29. |
| DOI: |
10.1177/2168479016680257 |
| Abstrakt: |
Ecuador is undergoing a process of clinical research development and strengthening. At the turn of the century, Ecuador experienced a favorable transition period of economic stability, which enabled advances in the health system and improvements in population welfare indicators. During this period, Ecuador created an institutional infrastructure to support the implementation and development of research projects. In turn, Ecuador created institutions, including the National Agency for Health Regulation, Control, and Surveillance (Agencia Nacional de Regulación, Control y Vigilancia Sanitaria [ARCSA]), and regulations establishing clinical trial (CT) design, conduct, recording, and reporting parameters, whose compliance ensures the protection of the rights of research subjects and requires compliance with Good Clinical Practice (GCP). Ecuador has favorable conditions for fostering the development of clinical research. The regulation of CTs is a process undergoing consistent changes toward harmonization with international standards and quality assurance. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink